Singapore, May 21, 2010: A gene centric life sciences company OriGene Technologies said that the company with the support of Wuxi Biopharmaceutical R&D Outsourcing Services Park (China), will build one of the largest and most sophisticated monoclonal antibody (MAb) production centers in the world in Wuxi, China.

MAbs have become an invaluable tool for researchers to develop diagnostic and therapeutic applications. The new, high-throughput production facility is expected to have over 1000 employees with the capacity to produce over 20,000 TrueMAB antibodies per year.

According OriGene, TrueMAB antibodies are generated using its large collection of full-length human proteins as primary antigens that have been affinity purified under native conditions to preserve natural protein conformations. As a result, TrueMAB antibodies provide higher sensitivity and specificity for the recognition of native epitopes on the protein's natural conformational structures.